Profile: InterMune Inc (ITMN.OQ)
7 Mar 2014
InterMune, Inc. (InterMune), incorporated on April 23, 2001, is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, the Company began the commercial launch of Esbriet in Canada. June 19, 2012, the Company completed the divestiture of its worldwide development and commercialization rights to the pharmaceutical product containing Interferon Gamma-1b sold by the Company under the tradename Actimmune. On June 19, 2012, the Company sold the rights of Actimmune (interferon gamma-1b) to Vidara Therapeutics International Limited.
IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The cause of IPF is unknown. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics.
The Company competes with Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., Boehringer Ingelheim, Celgene, Janssen, Fibrogen, Sanofi, Novartis and Stromedix.
3280 Bayshore Blvd
BRISBANE CA 94005